Advertisement

Immunologic Research

, Volume 36, Issue 1–3, pp 247–254 | Cite as

Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles

  • Eva Wieckowski
  • Theresa L. Whiteside
Article

Abstract

Microvesicles (MV) or exosomes are produced and secreted by tumor and normal cells. The molecular profile and functions of tumor-derived vs dendritic cell (DC)-derived MV are distinct. The former express death ligands and mediate apoptosis of activated T cells. The latter promote CD4+T cell proliferation and may play a role in regulating T cell responses. Serving as intercellular communication networks, tumor-derived MV contribute to tumor escape, while DC-derived MV drive and regulate immune response.

Key Words

Exosomes Microvesicles Human tumors Dendritic cells T cells Apoptosis 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Taylor DD, Black PH: Neoplastic and developmental importance of plasma membrane vesicles. Am Zool 1987;26:411–415.Google Scholar
  2. 2.
    Taylor DD, Black PH: Shedding of plasma membrane fragments. Neoplastic and developmental importance. Dev Biol 1986;3:33–57.Google Scholar
  3. 3.
    Taylor DD, Akyol S, Gercel-Taylor C: Pregnancy-associated exosomes and their modulation of T cell signaling. J Immunol 2006;176:1534–1542.PubMedGoogle Scholar
  4. 4.
    Lin SP, Almqvist N, Telemo E: Human small intestinal epithelial cells constitutively express the key elements for antigen processing and the production of exosomes. Blood Cells Mol Dis 2005;35:122–128.PubMedCrossRefGoogle Scholar
  5. 5.
    Thery C, Duban L, Segura E, Veron P, Lantz O, Amigorena S: Indirect activation of naïve CD4+T cells by dendritic cell-derived exosomes. Nat Immunol 2002; 3:1156–1162.PubMedCrossRefGoogle Scholar
  6. 6.
    Thery C, Zitvogel L, Amigorena S: Exosomes: Composition, biogenesis, and function. Nat Rev Immunol 2002; 2:569–579.PubMedGoogle Scholar
  7. 7.
    Wiley RD, Gummuluru S: Immature dendritic cellderived exosomes can mediate HIV-1 trans infection. Proc Natl Acad Sci USA 2006;103:738–743.PubMedCrossRefGoogle Scholar
  8. 8.
    Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C: Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem 1987;262:9412–9420.PubMedGoogle Scholar
  9. 9.
    Zitvogel L, Regnault A, Lozier A, et al: Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived ex oxomes Nat Med 1998; 4:594–600.PubMedCrossRefGoogle Scholar
  10. 10.
    Chaput N, Schartz NE, Andre F, Zitvogel L: Exosomes for immunotherapy of cancer. Adv Exp Med Biol 2003; 532:215–221.PubMedGoogle Scholar
  11. 11.
    Hsu DH, Paz P, Villaflor G, et al: Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. J Immunother 2003;26:440–450.PubMedCrossRefGoogle Scholar
  12. 12.
    Taylor DD, Gercel-Taylor C: Tumour-derived exosomes and their role in cancer-associated T-cell signaling defects. Br J Cancer 2005;92:305–311.PubMedGoogle Scholar
  13. 13.
    Whiteside TL. Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system?. Br J Cancer 2005;92:209–211.PubMedCrossRefGoogle Scholar
  14. 14.
    Whiteside TL: Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic interventions. Sem Cancer Biol 2006;16:3–15.CrossRefGoogle Scholar
  15. 15.
    Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL: Signaling abnormalities and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002; 8:3137–3145.PubMedGoogle Scholar
  16. 16.
    Kim J-W, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL: FasL+membraneous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 2005;11:1010–1020.PubMedGoogle Scholar
  17. 17.
    Gastman BR, Atarashi Y, Reichert TE, et al: Fas ligand is expressed on human squamous cell carcinomas of the head and neck and it promotes apoptosis of T lympocytes. Cancer Res 1999;59:5356–5364.PubMedGoogle Scholar
  18. 18.
    Andre F, Chaput N, Schartz NE, et al: Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cellderived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 2004; 172:2126–2136.PubMedGoogle Scholar
  19. 19.
    Andreola G, Rivoltini L, Castelli C, et al: Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002;195: 1303–1316.PubMedCrossRefGoogle Scholar
  20. 20.
    Martinez-Lorenzo MJ, Anel A, Alava MA, et al: The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp Cell Res 2004;295:315–329.PubMedCrossRefGoogle Scholar
  21. 21.
    Huber V, Fais S, Iero M, et al: Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 2005;128:1796–1804.PubMedCrossRefGoogle Scholar

Copyright information

© Human Press Inc 2006

Authors and Affiliations

  1. 1.Department of Pathology, Immunology and OtolaryngologyUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Hillman Cancer CenterUniversity of Pittsburgh Cancer InstitutePittsburgh

Personalised recommendations

Cite article

Buy options